A Monte Carlo Analysis of Peritoneal Antimicrobial Pharmacokinetics

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 696)


Peritoneal dialysis-associated peritonitis (PDAP) can be treated using very different regimens of antimicrobial administration, regimens that result in different pharmacokinetic outcomes and systemic exposure levels. Currently, there is no population-level pharmacokinetic framework germane to the treatment of PDAP. We coupled a differential-equation-based model of antimicrobial kinetics to a Monte Carlo simulation framework, and conducted “in silico” clinical trials to explore the anticipated effects of different antimicrobial dosing regimens on relevant pharmacokinetic parameters (AUC/MIC and time greater than 5 ×MIC) and the level of systemic exposure.


Peritoneal dialysis In silico clinical trial 



This study is supported by NIH 7R21AI055818-02.


  1. 1.
    Ota K, Mineshima M, Watanabe N, Naganuma S: Functional deterioration of the peritoneum: does it occur in the absence of peritonitis? Nephrol Dial Transplant 2:30–33, 1987PubMedGoogle Scholar
  2. 2.
    Selgas R, Fernandez-Reyes MJ, Bosque E, et al: Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 23:64–73, 1994PubMedGoogle Scholar
  3. 3.
    Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11:498–506, 1996PubMedGoogle Scholar
  4. 4.
    Finkelstein E, Jekel J, Troidel L, et al: Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis 39: 1278–1286, 2002PubMedCrossRefGoogle Scholar
  5. 5.
    Zelenitsky S, Barns L, Findlay I, et al: Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 36:1009–1013, 2000PubMedCrossRefGoogle Scholar
  6. 6.
    Golper T, Hartstein A: Analysis of the causative pathogens in uncomplicated CAPD-associated peritonitis: duration of therapy, relapses, and prognosis. Am J Kidney Dis 7:141–145, 1986PubMedGoogle Scholar
  7. 7.
    West TE, Walshe JJ, Krol CP, Amsterdam D: Staphylococcal peritonitis in patients on continuous peritoneal dialysis. J Clin Microbiol 23(5):809–812, 1986PubMedGoogle Scholar
  8. 8.
    Holley JL, Bernardini J, Johnston JR, Piraino B: Methicillin-resistant staphylococcal infections in an outpatient peritoneal dialysis program. Am J Kidney Dis 16:142–146, 1990PubMedGoogle Scholar
  9. 9.
    Pérez-Fontán M, Rosales M, Rodríguez-Carmona A, García Falcón T, et al.: Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 39:337–341, 2002Google Scholar
  10. 10.
    Sieradzki K, Roberts RB, Serur D, Hargrave J, et al: Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J Clin Microbiol 37:39–44, 1999PubMedGoogle Scholar
  11. 11.
    Tokors, JI, Frank M, Alter, M, Arduino, M: National surveillance of dialysis-associated diseases in the United States, 2000. Available at:; p 29
  12. 12.
    Tokars J: Infections due to antimicrobial-resistant pathogens in the dialysis unit. Blood Purif 18:355–360, 2000PubMedCrossRefGoogle Scholar
  13. 13.
    Tokars JI, Gehr T, Jarvis WR, et al: Vancomycin-resistant enterococci colonization in patients at seven hemodialysis centers. Kidney Int 60:1511–1516, 2001PubMedCrossRefGoogle Scholar
  14. 14.
    D’Agata EM, Green WK, Schulman G, et al: Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis 32(1):23–29, 2001PubMedCrossRefGoogle Scholar
  15. 15.
    Atta MG, Eustace JA, Song X, et al: Outpatient vancomycin use and vancomycin-resistant enterococcal colonization in maintenance dialysis patients. Kidney Int 59:718–724, 2001PubMedCrossRefGoogle Scholar
  16. 16.
    Wong S, Ho PL, Woo P, Yuen K: Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 29:760–767, 1999PubMedCrossRefGoogle Scholar
  17. 17.
    Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L: ISPD Ad Hoc Advisory Committee. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25(2):107–131, 2005Google Scholar
  18. 18.
    Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF: Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19(1):65–70, 1999PubMedGoogle Scholar
  19. 19.
    Grabe DW, Bailie GR, Eisele G, Frye RF: Pharmacokinetics of intermittent intraperitoneal ceftazidime. Am J Kidney Dis 33(1):111–117, 1999PubMedCrossRefGoogle Scholar
  20. 20.
    Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edition, edited by LL Bruton, McGraw-Hill, New York, 2006Google Scholar
  21. 21.
    Macdonald WA, Watts J, Bowmer MI: Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions. J Clin Microbiol 24:104–107, 1986Google Scholar
  22. 22.
    Watson SP, Clements MO, Foster SJ: Characterization of the starvation-survival response of Staphylococcus aureus. J Bacteriol 180:1750–1758, 1998Google Scholar
  23. 23.
    Clements MO, Foster SJ: Starvation recovery of Staphylococcus aureus 8325–4. Microbiology 144:1755–1763, 1998PubMedCrossRefGoogle Scholar
  24. 24.
    Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 47(12):3764–3767, 2003PubMedCrossRefGoogle Scholar
  25. 25.
    Glancey GR, Cameron JS, Ogg CS: Peritoneal drainage: an important element in host defense against staphylococcal peritonitis in patients on CAPD. Nephrol Dial Transplant 7: 627–631, 1992PubMedGoogle Scholar
  26. 26.
    Hotchkiss JR, Hermsen ED, Hovde LB, Simonson DA, Rotschafer JC, Crooke PS: Dynamic analysis of peritoneal dialysis associated peritonitis, ASAIO J 50(6):568–576, 2004PubMedCrossRefGoogle Scholar
  27. 27.
    Ariano RE, Franczuk C, Fine A, Harding GK, Zelenitsky SA: Challenging the current treatment paradigm for methicillin-resistant Staphylococcus epidermidis peritonitis in peritoneal dialysis patients. Perit Dial Int 22(3):335–338, 2002PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of MathematicsFisk UniversityNashvilleUSA

Personalised recommendations